Skip to main content
Erschienen in:

01.06.2019 | Clinical study

Chemotherapy with highest risk of peripheral neuropathy

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Tubulin-targeting agents and proteasome inhbitors are associated with the highest risk of chemotherapy-induced peripheral neuropathy (CIPN), according to a pooled analysis of data from Cancer Therapy Evaluation Program (CTEP)-sponsored phase I trials which was published in the European Journal of Cancer. …
Literatur
Metadaten
Titel
Chemotherapy with highest risk of peripheral neuropathy
Publikationsdatum
01.06.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-63551-5